JP2013537187A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537187A5
JP2013537187A5 JP2013527738A JP2013527738A JP2013537187A5 JP 2013537187 A5 JP2013537187 A5 JP 2013537187A5 JP 2013527738 A JP2013527738 A JP 2013527738A JP 2013527738 A JP2013527738 A JP 2013527738A JP 2013537187 A5 JP2013537187 A5 JP 2013537187A5
Authority
JP
Japan
Prior art keywords
cells
syngeneic
subject
respect
isolated population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013527738A
Other languages
English (en)
Japanese (ja)
Other versions
JP5977238B2 (ja
JP2013537187A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2011/000727 external-priority patent/WO2012032526A2/en
Publication of JP2013537187A publication Critical patent/JP2013537187A/ja
Publication of JP2013537187A5 publication Critical patent/JP2013537187A5/ja
Application granted granted Critical
Publication of JP5977238B2 publication Critical patent/JP5977238B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013527738A 2010-09-08 2011-09-08 抗白血病/リンパ腫処置のための抗第三者セントラルメモリーt細胞の使用 Active JP5977238B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38071610P 2010-09-08 2010-09-08
US61/380,716 2010-09-08
PCT/IL2011/000727 WO2012032526A2 (en) 2010-09-08 2011-09-08 Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment

Publications (3)

Publication Number Publication Date
JP2013537187A JP2013537187A (ja) 2013-09-30
JP2013537187A5 true JP2013537187A5 (https=) 2014-10-16
JP5977238B2 JP5977238B2 (ja) 2016-08-24

Family

ID=45002090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013527738A Active JP5977238B2 (ja) 2010-09-08 2011-09-08 抗白血病/リンパ腫処置のための抗第三者セントラルメモリーt細胞の使用

Country Status (15)

Country Link
US (2) US9421228B2 (https=)
EP (1) EP2613801B1 (https=)
JP (1) JP5977238B2 (https=)
KR (1) KR101788826B1 (https=)
CN (2) CN103282047B (https=)
BR (1) BR112013005756A2 (https=)
CA (1) CA2810632C (https=)
ES (1) ES2589678T3 (https=)
HU (1) HUE031063T2 (https=)
IL (1) IL225102A (https=)
MX (1) MX357746B (https=)
PL (1) PL2613801T3 (https=)
PT (1) PT2613801T (https=)
SG (1) SG188473A1 (https=)
WO (1) WO2012032526A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9738872B2 (en) 2008-10-30 2017-08-22 Yeda Research And Development Co. Ltd. Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
CN103282047B (zh) 2010-09-08 2016-08-24 耶达研究及发展有限公司 抗第三方中枢记忆性t细胞在抗白血病/淋巴瘤治疗中的用途
CA2823782C (en) 2011-01-10 2019-05-07 Samuel Strober Enhancement of allogeneic hematopoietic stem cell transplantation
WO2013035099A1 (en) 2011-09-08 2013-03-14 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
JP6142142B2 (ja) * 2012-04-10 2017-06-07 株式会社リンフォテック メモリーt細胞を主成分とするリンパ球細胞群の製造方法
EP3322424B1 (en) * 2015-07-16 2023-10-11 Yeda Research and Development Co., Ltd. Use of anti third party central memory t cells
IL263924B2 (en) 2016-06-27 2025-03-01 Yeda Res & Dev Voto cells produced from memory T cells
ES3064681T3 (en) 2017-01-18 2026-04-28 Yeda Res And Development Co Ltd Genetically modified veto cells and use of same in immunotherapy
US10751368B2 (en) 2017-01-18 2020-08-25 Yeda Research And Development Co. Ltd. Methods of transplantation and disease treatment
EP4417210A1 (en) * 2017-03-15 2024-08-21 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
MX2022005418A (es) * 2019-11-05 2022-08-15 Yeda Res & Dev Uso de celulas de veto para el tratamiento de la enfermedad de celulas falciformes.
JP2023500277A (ja) * 2019-11-05 2023-01-05 イェダ リサーチ アンド デベロップメント カンパニー リミテッド T細胞媒介性自己免疫疾患の治療におけるベト細胞の使用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5599703A (en) 1993-10-28 1997-02-04 The United States Of America As Represented By The Secretary Of The Navy In vitro amplification/expansion of CD34+ stem and progenitor cells
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
WO2000039294A1 (en) 1998-12-24 2000-07-06 Novartis Ag Porcine cells incapable of expressing cd40 antigen, for xenotransplantation
US6544506B2 (en) 2000-01-05 2003-04-08 Yeda Research & Development Co. Ltd. Veto cells effective in preventing graft rejection and devoid of graft versus host potential
AU2001253400B2 (en) 2000-04-11 2007-03-01 University Of Southern California A method to prevent graft rejection using tgf-beta to induce t suppressor cells
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
EP1935427B1 (en) 2000-07-03 2018-03-07 Bristol-Myers Squibb Company Uses of soluble CTLA4 mutant molecules
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
IL155941A0 (en) 2000-11-30 2003-12-23 Yeda Res & Dev Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease
US7304033B2 (en) 2001-05-23 2007-12-04 Bristol-Myers Squibb Company Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules
US20030147859A1 (en) 2001-06-18 2003-08-07 Yair Reisner Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance
SG144925A1 (en) 2003-08-04 2008-08-28 Bristol Myers Squibb Co Methods for treating cardiovascular disease using a soluble ctla4 molecule
BRPI0509274A (pt) 2004-03-26 2007-09-04 Pfizer Prod Inc usos de anticorpos anti-ctla-4
WO2006041763A1 (en) 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
EP1814580B1 (en) 2004-11-24 2016-08-10 Fred Hutchinson Cancer Research Center Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens
JP2008535841A (ja) 2005-04-06 2008-09-04 ブリストル−マイヤーズ スクイブ カンパニー 可溶性ctla4変異分子によるグラフト移植に関連する免疫不全の治療方法
US8916147B2 (en) 2005-08-24 2014-12-23 Yeda Research and Devolpment Co. Ltd. Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
GB0606776D0 (en) 2006-04-03 2006-05-10 Novartis Pharma Ag Predictive biomarkers for chronic allograft nephropathy
US20110165639A1 (en) * 2008-08-15 2011-07-07 Brijen Biotech, Llc Refinery process to produce biofuels and bioenergy products from home and municipal solid waste
US8200915B2 (en) 2008-08-22 2012-06-12 Cadence Design Systems, Inc. Management of very large streaming data sets for efficient writes and reads to and from persistent storage
US9738872B2 (en) 2008-10-30 2017-08-22 Yeda Research And Development Co. Ltd. Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
CN103282047B (zh) 2010-09-08 2016-08-24 耶达研究及发展有限公司 抗第三方中枢记忆性t细胞在抗白血病/淋巴瘤治疗中的用途
JP2013540731A (ja) 2010-09-08 2013-11-07 イェダ リサーチ アンド デベロップメント カンパニー リミテッド 安定かつ長期間の生着のための免疫抑制薬物組合せ
WO2013035099A1 (en) 2011-09-08 2013-03-14 Yeda Research And Development Co. Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment

Similar Documents

Publication Publication Date Title
JP2013537187A5 (https=)
JP7440027B2 (ja) 多能性幹細胞から免疫細胞療法用t細胞を誘導する方法
Guo et al. Regulatory T cells in GVHD therapy
JP2014526244A5 (https=)
JP6196620B2 (ja) 抗第三者セントラルメモリーt細胞、その作製方法ならびに移植および疾患処置におけるその使用
RU2011121630A (ru) Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
EP2613801B1 (en) Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
JP2016509840A5 (https=)
CN113454209A (zh) 通用型双阴性t细胞的制备和治疗用途
Agostini Stem cell therapy for chronic lung diseases: hope and reality
TW202130807A (zh) 具有cd45ra⁺及ccr7⁺之細胞表面標誌的t細胞之製造方法
Pera et al. Immune Responses to Persistent or
Zhang et al. Mouse Models of Hematopoietic Stem Cell Transplantation
dela Peña et al. Characterization of the phenotypic features, immuno-modulatory properties and therapeutic potentials of wharton’s jelly-derived mesenchymal stromal cells
ES2472452B1 (es) Procedimiento para la selección de linfocitos T antígeno-específicos mediante la identificación de dobletes.
RU2019101826A (ru) Вето-клетки, полученные из т-клеток памяти
Kudo et al. Induction of Macrophage-Like Immunosuppressive Cells from Mouse ES Cells That Contribute
Bruinsma Regulatory T cells and immune tolerance after allogeneic hematopoietic stem cell transplantation
HK1187528B (en) Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment
HK1200099B (en) Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment